Biostage Inc Stock News

Biostage, Inc. (OTC:BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer Confere

HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating

Biostage has filed to raise capital via an uplisting IPO to Nasdaq. The firm is developing treatments for the various gastrointestinal system and airway conditions.

Biostage, Inc. (OTC:BSTG) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Peter Pellegrino - Interim Vice President of Finance David Green - Interim Chief Executive Offic

HOLLISTON, Mass. , March 30, 2022 /PRNewswire/ --  Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in trea

Biostage <> shares have made a comeback after announcing that a Court ordered its medical liability insurance carrier, Medmarc, breached its duty to defend the company in a

Biostage (OTCMKTS:BSTG) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Insider and Institutional Ownership 0.3% of Biostage shares are owned by institutional investors. Comparatively, 83.3% of [] The post Reviewing Biostage (OTCMKTS:BSTG) & TELA Bio (NASDAQ:TELA) appeared first on ETF Daily News .

TELA Bio (NASDAQ:TELA) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Risk & Volatility TELA Bio has a beta of 1.66, suggesting that its share price is []

Biostage (OTCMKTS: BSTG) is one of 192 public companies in the Surgical & medical instruments industry, but how does it compare to its peers? We will compare Biostage to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk. Institutional & Insider Ownership 0.3% of Biostage shares []

Biostage (OTCMKTS: BSTG) is one of 192 public companies in the Surgical & medical instruments industry, but how does it compare to its peers? We will compare Biostage to related businesses based on the strength of its valuation, analyst recommendations, risk, institutional ownership, dividends, profitability and earnings. Valuation and Earnings This table compares Biostage and []

HOLLISTON, Mass., Aug. 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Ce

HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cell